Rationale and Background on Tumor-Treating Fields for Glioblastoma.
More than 150 years after the first description of glioma cells, patients with glioblastoma (GBM) continue to have a poor prognosis despite standard-of-care therapy. With the introduction of tumor-treating fields (TTFields) therapy for the treatment of recurrent GBM in 2011 and for newly diagnosed GBM in 2015, the opportunity to increase progression-free survival and overall survival while improving quality of life provides a welcome option.



This article describes how TTFields therapy may be used in the treatment of patients with recurrent GBM.



This article provides oncology nurses with two case studies that examine how TTFields therapy can be integrated into the overall treatment paradigm.



These two patient case studies demonstrate the autonomy and lack of adverse effects that TTFields therapy offers to patients with GBM.
Northwestern Memorial Hospital Brain Tumor Institute.
Margaret A
MA
Schwartz
Northwestern Memorial Hospital Brain Tumor Institute.
Lynnette
L
Onuselogu
D000328:Adult; D001932:Brain Neoplasms / Q000628:therapy*; D004599:Electric Stimulation Therapy; D004574:Electromagnetic Fields; D005260:Female; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009859:Oncology Nursing / Q000379:methods*; D016896:Treatment Outcome
Optune; TTFields; alternating electric fields; glioblastoma; tumor-treating fields